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Defective Decatenation Checkpoint Function
Is a Common Feature of Melanoma
Kelly Brooks1,3, Kee Ming Chia1, Loredana Spoerri1, Pamela Mukhopadhyay1, Matthew Wigan1,
Mitchell Stark2, Sandra Pavey1 and Brian Gabrielli1
A hallmark of cancer is genomic instability that is considered to provide the adaptive capacity of cancers to thrive
under conditions in which the normal precursors would not survive. Recent genomic analysis has revealed a very
high degree of genomic instability in melanomas, although the mechanism by which this instability arises is not
known. Here we report that a high proportion (68%) of melanoma cell lines are either partially (40%) or severely
(28%) compromised for the G2 phase decatenation checkpoint that normally functions to ensure that the sister
chromatids are able to separate correctly during mitosis. The consequence of this loss of checkpoint function is a
severely reduced ability to partition the replicated genome in mitosis and thereby increase genomic instability.
We also demonstrate that decatenation is dependent on both TopoIIa and b isoforms. The high incidence of
decatenation checkpoint defect is likely to be a major contributor to the high level of genomic instability found in
melanomas.
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INTRODUCTION
One of the hallmarks of cancer is loss of cell cycle regu-
lation (Hanahan and Weinberg, 2011), particularly cell cycle
checkpoint mechanisms that are commonly disrupted.
The loss of these mechanisms has the potential to increase
genetic instability, as many are involved in ensuring accurate
replication and segregation of the DNA. The G2-phase
checkpoint in particular is considered an important guardian
of the genome, inhibiting cell division in the presence of DNA
damage, catenations, and other genetic aberrations (Bucher
and Britten, 2008). Catenated chromosomes are one of the
features monitored in G2 phase that can activate a G2-phase
checkpoint response termed the decatenation checkpoint.
Catenations or tangling of replicated sister chromatids is a
normal consequence of DNA replication owing to the double
helical nature of DNA (Wang, 2002). Resolution of these
catenations before mitosis is essential for normal chromosome
condensation and to ensure the fidelity of sister chromatid
segregation (Nakagawa et al., 2004; Damelin and Bestor,
2007. Failure to properly decatenate sister chromatids has
been proposed to lead to nondisjunction of sister chromatids,
loss of heterozygosity, anueploidy, and translocations, all
sources of genetic instability (Bower et al., 2010).
Decatenation of the sister chromatids is performed by
topoisomerase II (TopoII) that forms a DNA–protein complex,
cleaving one sister chromatid and passing the other through
the cleavage site to facilitate decatenation (Downes et al.,
1994; Deming et al., 2001; Wang, 2002; Damelin and Bestor,
2007; Bower et al., 2010). Two TopoII isoforms exist: the
a isoform whose expression peaks at the G2/M phase and
is thought to be the predominant isoform for decatenation
(Bower et al., 2010), and the b isoform that is stably
expressed throughout the cell cycle (Austin and Marsh,
1998). Insufficient resolution of the sister chromatids results
in a G2-phase delay through the activation of the decatenation
checkpoint, preventing catenated chromatids entering mitosis
(Downes et al., 1994; Gimenez-Abian et al., 2002). Decate-
nation can be specifically inhibited using the TopoII catalytic
inhibitors bisdioxopiperazines, including ICRF-193 (Downes
et al., 1994).
Previous use of these inhibitors in cancer cells has suggested
that a defective decatenation checkpoint may be a common
feature of some cancers, which could increase the levels of
genomic instability (Doherty et al., 2003; Nakagawa et al.,
2004). Here we have examined the functional status of the
decatenation checkpoint in a large panel of melanoma cell
lines, and demonstrate a high proportion (B68%) to have a
defective checkpoint response that resulted in aberrant
cell division upon inhibition of decatenation. The role of
the TopoII isoforms in the decatenation is also examined,
and we show that both are required to resolve catenated
chromosomes and allow normal partitioning of the genome
in mitosis.
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RESULTS
To determine the functional status of the G2-phase decatena-
tion checkpoint in melanoma, a panel of melanoma cell lines
were treated with the TopoII catalytic inhibitor ICRF-193 and
assessed for a G2-phase arrest. A dose of 2mM was sufficient to
induce a 4N DNA accumulation when DNA content was
assessed by flow cytometry, indicative of either a G2-phase
decatenation checkpoint arrest or, where the checkpoint was
defective, failed cytokinesis owing to failure to separate the
catentated sister chromatids. To discriminate between these
outcomes, activation of the G2-phase decatenation checkpoint
was assessed biochemically in a panel of melanoma cell
lines by the accumulation of markers of G2-phase, inactive
Tyr15-phosphorylated Cdk1 and Cyclin B1, in conjunction
with time-lapse microscopy to quantify the delay of entry into
mitosis. In decatenation checkpoint–functional cell lines, a
transient accumulation of Tyr15-phosphorylated Cdk1 and
Cyclin B1 was observed between 8 and 16 hours after drug
addition (Figure 1a), whereas no changes in these G2-phase
markers were observed in the checkpoint-defective lines
(Figure 1a). Similar biochemical evaluation was performed
for the checkpoint-competent MM329 and MM603, and
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Figure 1. Decatenation checkpoint is defective in melanoma cell lines.
(a) Whole-cell lysates of cells treated with 2mM ICRF-193 for 8, 12, 16, and
20 hours were immunoblotted for markers of G2-phase arrest: Cyclin B1 and
phosphorylated Tyr15 Cdk1 (pY15). Etoposide (Etop)-treated samples were
included as a positive control for G2-phase checkpoint arrest. (b) Cells were
treated with 2mM ICRF-193 for 10 or 24 hours, with 1 mM Etop for 24 hours,
or with DMSO as G2-phase checkpoint arrested and untreated controls.
(c) The percentage of cells in each cell cycle phase is shown.
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Figure 2. Decatenation checkpoint is commonly defective in melanoma cell
lines. (a) Cells were treated with 2mM ICRF-193 (gray lines) or with an
equivalent volume of DMSO (black lines), followed immediately by time-lapse
microscopy. The time of entry into mitosis and the cumulative mitotic cell
index are shown for the checkpoint-functional A2058 and checkpoint-defective
SKMel13 melanoma cell lines. (b) Comparison of strength of decatenation
checkpoint arrest induced by ICRF-193 treatment between cell lines expressed
as a percentage of doubling time. The cell lines with error bars are mean
and SE of at least three independent experiments.
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defective A02, HT144, and D25 (Supplementary Figure S1A
online, and data not shown). Some cell lines (e.g., MM383)
appeared to have a transient accumulation of G2-phase
markers at 10 hours, suggesting an ability to initiate but not
maintain the G2-phase arrest (Supplementary Figure S1A
online).
Flow cytometry of treated cells also demonstrated the
transient nature of the G2-phase delay in the checkpoint-
functional A2058, MM329, and MM603 cells, with a strong
accumulation of cells with 4N DNA content at 10 hours after
treatment, which reduced toward control levels by 24 hours
(Figure 1b and Supplementary Figure S1 online). The check-
point-defective lines also had a strong accumulation of cells
with 4N DNA content at 10 hours, which remained elevated
at 24 hours.
Time-lapse microscopy was used to determine the extent of
the delay and the effect of the transient G2-phase delay on the
subsequent mitosis. Quantitative analysis of the cumulative
mitotic index revealed that checkpoint-functional melanoma
cell lines (A2058 and MM329) and primary cultures of
neonatal foreskin fibroblasts had a delayed entry into mitosis,
demonstrated by the separation of the DMSO- and ICRF-193-
treated sample plots (Figure 2a and Supplementary Figure S2
online). Decatenation checkpoint-defective cell lines
(SKMel13 and A02) had little or no delay, demonstrated by
the overlapping cumulative mitotic index. To more precisely
characterize these cell lines as checkpoint functional or
defective, the time taken for both DMSO- and ICRF-193-
treated cells to reach 30% mitotic accumulation was calcu-
lated and expressed as a percentage of doubling time for each
cell line. Using this method, 25 melanoma cell lines plus
neonatal foreskin fibroblasts and HeLa cells were assessed
(Supplementary Table S1 online). The severely decatenation
checkpoint-defective lines (e.g., SKMel13, HT144, A02, and
MM415) had delays in entering mitosis of o6% of their
doubling times and represented 7/25 (28%) of the cell lines,
whereas the checkpoint-functional cell lines (e.g., A2058,
MM329, and MM603) had delays of 420% of their doubling
times and represented 8/25 (32%) of the assessed cell lines
(Figure 2b).
A group with very similar delays (delays from B6.5 to
B13% of doubling time, a majority with delays of B11% of
doubling time) appeared partially checkpoint defective. Com-
parative gene expression analysis and clustering was used to
determine the functional classification that this intermediate
group reflected, to allow for a more definitive determination
of the frequency of this defect. A class comparison was
performed for the seven checkpoint-defective versus the eight
checkpoint-functional cell lines using gene expression data
generated on the Affymetrix U133 Plus 2.0 array (Pavey et al.,
2004; Johansson et al., 2007; Packer et al., 2007), using
Bayesian-adjusted t-statistics. The differentially expressed
genes were then ranked based on significance using their
b-value (see Supplementary Material online for details). The
gene list from the class comparison was used as a signature for
performing an unsupervised hierarchical clustering of all cell
lines. The use of the top 50 genes based on b-value ranking
(Supplementary Table S2 online) resulted in the partial group
clustering with the checkpoint-defective group (Supplemen-
tary Figure S3 online). This showed the partially checkpoint-
defective cell lines to be transcriptomically more similar to the
checkpoint-defective cell lines, indicating that the majority of
melanoma cell lines (68%) were either severely or partially
defective in their decatenation checkpoint.
The transient nature of the decatenation checkpoint arrest
in the checkpoint-functional cell lines indicated that cells
completed decatenation and inactivated the checkpoint to
progress through mitosis normally even in the presence of the
TopoII inhibitor. Mitotic chromosome spreads from two
checkpoint-functional (MM329 and A2058) cell lines showed
little difference after treatment with either 2mM ICRF-193 or
DMSO control; the ICRF-193-treated chromosomes appeared
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Figure 3. Failure to separate sister chromatids in ICRF-193-treated checkpoint-defective cells. Mitotic chromosome spread of DMSO- and 2mM ICRF-193-treated
cells. Cells were treated for 24 hours with ICRF-193, and enrichment for mitotic cells was achieved by 500mg ml 1 nocodazole treatment for 2 hours before
harvesting. (a) MM329 and A2058 decatenation checkpoint-functional cell lines. (b) SKMel13 and MM415 decatenation checkpoint–defective cell lines.
The white bar in A2058 control represents 10mm. All images are of equivalent magnification.
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a little less compacted, although the individual chromosome
arms were readily discernible (Figure 3a), demonstrating
the normal completion of decatenation. In contrast, the two
checkpoint-defective cell lines (SKMel13 and MM415)
showed defects from failure to separate the chromosome arms
of the sister chromatids to highly tangled chromosomes
(Figure 3b), indicating the presence of unresolved catenations
between the sister chromatids in the checkpoint-defective cell
lines in mitosis. One expected outcome of this would be that
the checkpoint-defective cell lines should not be able
to proceed normally through mitosis in the presence of
ICRF-193 owing to their inability to partition their catenated
chromosomes. This would be expected to trigger the spindle
assembly checkpoint, arresting in mitosis. The checkpoint-
functional cell lines should have no mitotic delay. Time-lapse
microscopy revealed that in the presence of either 2 or 10mM
ICRF-193 there was little delay in mitosis in either checkpoint-
functional or -defective cell lines (Supplementary Figure S4
online). Nocodazole treatment demonstrated that each cell
line was capable of activating a spindle assembly checkpoint.
Cotreatment of nocodazole with ICRF-193 did not affect the
mitotic arrest induced by nocodazole in either checkpoint-
competent or -defective cell lines. This demonstrates that the
failure to arrest in mitosis was due to a failure of the spindle
assembly checkpoint to recognize the catenated chromo-
somes as a mitotic failure rather than an intrinsic property of
ICRF-193 to overcome the spindle assembly checkpoint arrest
(data not shown).
TopoII protein levels have previously been reported to be
responsible for the sensitivity to TopoII inhibitors (Morgan
et al., 2000). To ensure that the lack of checkpoint arrest was
not a consequence of different TopoII levels, the levels of
TopoIIa and TopoIIb were examined. The absolute level of
TopoIIa varied from cell line to cell line, and there was no
consistent effect of drug treatment on TopoIIa levels
(Supplementary Figure S5 online). However, a consistent
reduction in the level of the TopoIIb isoform with ICRF-193
treatment was observed in all melanoma cell lines investi-
gated. The effect of ICRF-193 on TopoIIb was rapid, with
maximal reduction observed by 8 hours, and recovering to
control levels between 24 and 48 hours after drug addition
(Supplementary Figure S6A online). The recovery of TopoIIb
levels was in part due to the instability of ICRF-193 in the
medium, as preincubation for 24 and 48 hours reduced its
ability to destabilize TopoIIb (Supplementary Figure S6B online).
The reduction in TopoIIb levels was a result of decreased
stability of the protein that could be stabilized by the protea-
some inhibitor MG132 (Supplementary Figure S6C online).
The literature has suggested that the TopoIIa isoform is
primarily responsible for G2-phase decatenation, based on the
ability of specific mutants or knockdown of TopoIIa to cause
insensitivity to ICRF inhibitors or loss of decatenation check-
point function (Grauslund et al., 2007; Luo et al., 2009; Bower
et al., 2010). As TopoIIb was degraded upon ICRF-193 treat-
ment, the potential contribution of TopoIIb to decatenation
may have been overlooked. To address this, the contribution
of both TopoII isoforms to the decatenation checkpoint and
to promoting normal cytokinesis was examined. TopoIIa and
TopoIIb were knocked down individually or in combination in
A2058 cells, and the outcome of cytokinesis was assessed.
Although a 90% knockdown of TopoIIa was achieved, the
best knockdown achieved for TopoIIb under various
conditions was 50% (Figure 4a). Knockdown of TopoIIa alone
produced a modest increase in the proportion of cells with 4N
DNA content, indicative of failed cytokinesis, whereas knock-
down of TopoIIb alone had little effect. Surprisingly, the
combination of TopoIIa and TopoIIb knockdown resulted in
an even greater accumulation of 4N cells than TopoIIa alone,
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Figure 4. Topoisomerase IIa (TopoIIa) and TopoIIb are required for
decatenation. (a) Immunoblotting of whole-cell lysates for TopoIIa, TopoIIb,
and a-Tubulin loading control in cells transfected with nontargeting (NS),
TopoIIa or TopoIIb small interfering RNA (siRNA), or both (aþ b) siRNAs.
The arrowhead indicates a nonspecific band. (b) Propidium iodide (PI) FACS
for DNA content of A2058 cells transfected with nonsense, TopoIIa, TopoIIb,
or combined TopoIIa and TopoIIb siRNAs. The percentage of cells in G2 phase
is shown. (c) Quantification of mitotic outcomes from immunofluorescence of
A2058 cells transfected with nonsense, TopoIIa, TopoIIb, or combined TopoIIa
and TopoIIb siRNAs. Staining for DNA with 4’,6-diamidino-2-phenylindole
(DAPI), centromeres with human ACA serum, cytoskeleton with a-tubulin, and
centromeres and midbodies with Aurora B. Sample image is shown. Over 100
cells were assessed in each of three separate experiments for the presence of
micronuclei or multiple nuclei, or DNA bridges containing ACA staining. Scale
bar¼ 10mm. ACA, anti-centromere antibodies.
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suggesting a role for TopoIIb in the absence of TopoIIa
(Figure 4b). A similar trend was seen in nuclear abnormalities
indicative of abnormal cytokinesis. TopoIIa alone caused a
small increase in abnormalities associated with persistent
catenations. TopoIIb knockdown alone had little effect,
whereas the combination resulted in 50% of cells with nuclear
abnormalities, especially the more severe abnormalities such
as DNA bridges and multinuclear cells (Figure 4c).
The accumulation of cells with 4N DNA content in the
decatenation checkpoint-defective cell lines suggested that
these cells are failing cytokinesis after attempting to segregate
catenated chromosomes during mitosis. To confirm the occur-
rence and frequency of aberrant mitosis/failed cytokinesis,
ICRF-193-treated cells were analyzed by immunofluorescent
staining for DNA to examine nuclear morphology, human
anti-centromere antibodies serum to highlight centromeres, a-
tubulin for the cytoskeleton/mitotic spindle, and Aurora B as a
marker of both centromeres early in mitosis and the midbody
during cytokinesis. Two checkpoint-functional (MM329 and
A2058) and two checkpoint-defective (A02 and MM415) cell
lines were treated with either 2mM ICRF-193 or a DMSO
control for 8 hours. The frequency of each phase of mitosis,
including cytokinesis, was then scored for each cell line and
treatment. Little change was observed in the proportion of
cells in the early stages of mitosis between DMSO and ICRF-
193 (Figure 5a and b), but there was a striking defect in
cytokinesis in the checkpoint-defective cell lines. Although
checkpoint-functional cell lines generally underwent normal
cytokinesis after ICRF-193 treatment, in the two checkpoint-
defective cell lines (A02 and MM415) there was a significant
increase (from 2% in controls to 20–40% with ICRF-193) in
abnormal cytokinesis. This involved the segregation of the
cytoplasm into two cells (as demonstrated by the presence of a
midbody marked with Aurora B) in the absence of any
segregation of the DNA (karyokinesis), resulting in the forma-
tion of one cell with 4N DNA complement and one cell with
no DNA, termed a cytoplast (Figure 5b). This aberrant
cytokinesis was also observed in the decatenation
checkpoint–defective SKMel13 line stably expressing GFP-
H2B to visualize the chromatin when followed by time-lapse
microscopy. Cells underwent normal cytokinesis in the
absence of ICRF-193, but half of the cytokinesis in the ICRF-
193-treated cells showed a failure of karyokinesis and cyto-
plast production (Figure 6a and b). The formation of cytoplasts
in the decatenation checkpoint-defective cell lines represents
a severe mitotic defect that appears to be a common
consequence of cells progressing through mitosis with cate-
nated chromosomes.
DISCUSSION
Catenations are a normal consequence of DNA replication
(Wang, 2002). Under normal conditions, cells ensure that
Figure 5. Loss of decatenation checkpoint results in failed cytokinesis. (a) Comparison of different stages in mitosis (Abnormal, failed cytokinesis; Ana A, anaphase
A; Ana B, anaphase B; Meta, metaphase; Cytokinesis, normal; Pro, prophase; as observed for DMSO-treated cells (filled bars) and 2mM ICRF-193-treated cells
(open bars). More than 100 cells were counted per cell line per treatment. MM329 and A2058 are decatenation checkpoint–competent cell lines, and A02
and MM415 are checkpoint-defective cell lines. (b) Immunofluorescence of cells treated with DMSO or 2mM ICRF-193. Nuclear stain using 4’,6-diamidino-2-
phenylindole (DAPI), a-tubulin staining for cytoskeleton, ACA serum staining for centromeres, and Aurora B staining for centromeres and midbodies.
Representative images for A2058 decatenation checkpoint-functional cell line and A02 decatenation checkpoint–defective cell line. Scale bars¼ 5mm. ACA, anti-
centromere antibodies.
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Figure 6. Decatenation checkpoint–defective cells undergo unequal partitioning of their DNA in cytokinesis. (a) SKMel13 cells stably expressing GFP-H2B
were treated with either DMSO (Control) or 2mM ICRF-193, followed by time-lapse microscopy. The frames were taken every 20 minutes. Scale bar¼10mm.
(b) Quantification of three similar movies to a, DMSO control (filled bars), ICRF-193 treated (open bars).
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these catenations are resolved before progression through
mitosis, via monitoring by the G2-phase decatenation check-
point. Failure to detect and appropriately respond to these
catenations has been suggested to increase genomic instability
(Downes et al., 1994; Deming et al., 2001; Gimenez-Abian
et al., 2002; Wang, 2002; Franchitto et al., 2003). We have
shown that decatenation checkpoint-defective cell lines
displayed dramatic increases in abnormal nuclear morpho-
logies or completely failed to segregate their DNA when
TopoII activity is inhibited. Under normal physiological
conditions, such a severe failure of decatenation is unlikely
to occur, but the presence of even a few undetected catenated
chromosomes will produce chromosome breakages and
aneuploidy, the result of failed mitotic division, as previously
proposed (Deming et al., 2001; Hajji et al., 2003; Clarke
et al., 2006). The severity of the defect observed with
complete inhibition of decatenation highlights the impor-
tance of the decatenation checkpoint in maintaining genetic
stability.
Quantitative assessment of decatenation checkpoint func-
tion using time-lapse microscopy has revealed degrees of
checkpoint defect not previously identified from biochemical
assessment. The majority of cell lines had either a completely
or a partially defective decatenation checkpoint, with only
B1/3 of cell lines retaining an intact checkpoint arrest. The
lack of cell cycle arrest was not caused by a lack of sensitivity
to the TopoII inhibitors; the accumulation of cells with 4N
DNA content and morphological features of failure to partition
the genome at mitosis, and lack of consistent increase in
the levels of either TopoII isoform previously proposed to
cause a loss of sensitivity to ICRF-193 (Wray et al., 2009a,b)
both point to failure of the decatenation checkpoint. The
checkpoint-functional cell lines were defined by the duration
of their checkpoint delay and ability to completely decatenate
their DNA. The partially defective checkpoint groups repre-
sent a less severe defect in either detection or signaling.
Surprisingly, none of the known decatenation checkpoint
genes MDC1, WRN, ATR, CHK1, ATM, CHK2, and BRCA1
were found to be differentially expressed between the
checkpoint-functional and -defective cells, and immuno-
blotting for ATR, WRN, BRCA1, and ATM did not reveal
any consistent changes in levels (data not shown). This
suggests that the gene expression changes between the
functional and defective groups may reflect changes that
compensate for the lack of checkpoint function rather than
changes responsible for the loss of the checkpoint arrest. The
similarity of the gene expression pattern of the defective and
partially defective groups suggests that many of the gene
expression changes required to compensate for the lack of
the decatenation checkpoint are also required in the less
severely compromised checkpoint response. Spindle assembly
checkpoint activation is required to trigger apoptosis in cells
that undergo a defective mitosis (Vogel et al., 2005; Gabrielli
et al., 2007). Thus, the lack of a mitotic spindle assembly
checkpoint arrest in the ICRF-193-treated checkpoint-
defective cell lines, despite the severely compromised
mitosis, is also likely to contribute to the survival of these
cells with increased genomic instability. Previous studies have
indicated that ICRF-193 functions specifically through TopoIIa
inhibition (Grauslund et al., 2007; Bower et al., 2010). The
degradation of TopoIIb after ICRF-193 treatment confirmed
previous reports (Xiao et al., 2003), suggesting a role for
TopoIIb in the decatenation checkpoint imposed by ICRF-193.
Depletion of TopoIIa had a minor effect on decatenation,
whereas TopoIIb depletion had no effect. Codepletion,
however, had a significant effect, although less than that
seen with ICRF-193. This provides strong evidence that both
TopoII isoforms contribute to the decatenation mechanism,
and that the destabilization of TopoIIb is a significant
contributor to the inhibition of decatenation observed with
this drug.
Attempts to segregate catenated chromosomes result in
increased DNA damage (Hajji et al., 2003). We have
recently reported that many melanoma cell lines have
adapted to tolerate high levels of endogenous DNA damage
(Brooks et al., 2012), possibly incurred as the result of a
defective decatenation checkpoint. This adaption to high
levels of DNA damage may underlie the clinical observation
that melanomas are generally tolerant of genotoxic therapies.
The rapidly developed resistance to targeted therapies such as
the BRAF inhibitors (Fedorenko et al., 2011; McMahon, 2011)
also suggests a profound capacity for adaptation. This may be
a direct product of the high levels of genetic instability
observed in melanomas (Stark and Hayward, 2007; Gast
et al., 2010), which could also be a consequence of
checkpoint loss. Further investigation is required to fully
understand how the defective decatenation checkpoint may
influence therapeutic responses, but the common occurrence
of this loss strongly suggests that this may be an important step
in the pathogenesis of melanoma allowing for a high level of
genomic instability.
MATERIALS AND METHODS
Cell lines and culturing conditions
All human melanoma cell lines were kindly provided by Professor
Nick Hayward and Dr Chris Schmidt (Queensland Institute of
Medical Research (QIMR), Brisbane, Australia) and are available
from the Australasian Biospecimen Network (Oncology). C044 and
G361 cell lines were kindly supplied by Dr Rick Pearson (Peter
MacCallum Cancer Institute, Melbourne, Australia). All melanoma
cell lines were cultured in RPMI-1640 medium (Invitrogen, Mulgrave,
Victoria, Australia) containing 10% Serum Supreme (Biowittakter,
Melbourne, Victoria, Australia), 2.5 mM HEPES (Invitrogen), 1 mM
sodium pyruvate (Gibco, Mulgrave, Victoria, Australia), and 2 mM L-
glutamine (Gibco). All cell lines were confirmed to be mycoplasma
free. Primary cultures of neonatal foreskin fibroblasts and HeLa cells
were cultured in DMEM with the same supplements as above.
SKMel13 cells expressing GFP-H2B were derived as described
previously (Stevens et al., 2008).
Time-lapse microscopy
Cells were seeded in multiwell tissue culture plates, and time-lapse
microscopy was performed using a Zeiss Axiovert 200 M Cell
Observer (North Ryde, New South Wales, Australia) equipped with
an incubation chamber at 37 1C and 5% CO2. Images were taken at
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intervals of 10–15 minutes using a Zeiss AxioCam at  10 objective.
Cells treated with 2mM ICRF-193 (Biomol, Waterloo, New South
Wales, Australia), 2 mg ml 1 nocodazole (Sigma Aldrich, Castle Hill,
New South Wales, Australia), or equivalent DMSO volumes were
analyzed. Images were analyzed using a minimum of 200 cells per
cell line and per treatment, tracked for mitotic accumulation (time of
entry into mitosis), and the duration of mitosis was determined.
Calculation of the G2 phase is presented in the Supplementary
Material online.
Flow cytometry
For cellular DNA content analysis, total cell pellets (floating and
adhered) were collected and fixed in 70% ethanol ( 20 1C), and were
stained and analyzed as reported previously (Gabrielli et al., 1996).
Immunoblotting
Total cell pellets were lysed in NETN lysis buffer (100 mM NaCl, 2 mM
EDTA, 20 mM Tris, and 0.5% Nonidet P-40) with 1 mM phenylmethyl-
sulfonyl fluoride, Protease inhibitor cocktail (Sigma Aldrich), 0.1%
SDS, 100 mM NaCl, 0.3 mM Na3VO4, 25 mM NaF, and 25 mM b-
glycerphosphate, resolved using SDS-PAGE gel electrophoresis, and
transferred to nitrocellulose membranes. Antibodies to Cyclin B1
(Gabrielli et al., 1996), Cdk1 (Santa Cruz, Scoresby, Victoria,
Australia), pCdk1Tyr15 and TopoIIa (Cell Signaling, Arundel,
Queensland, Australia), TopoIIb (Bethyl Laboratories, Murarrie,
Queensland, Australia), and a-Tubulin (Sigma Aldrich) were used.
Proteins were visualized using chemiluminescence detection (Perkin
Elmer, Glen Waverley, Victoria, Australia). Protein levels were
quantified using ImageJ (http://rsbweb.nih.gov/ij/) software.
Transfection
Cells were reverse transfected with 25 nM Dharmacon ON-TARGET-
plus SMARTpool small interfering RNAs (siRNAs), Nontargeting
Control pool, TopoIIa, and Ambion Silencer Select siRNA against
TopoIIb using Dharmafect2 Lipofection reagent as per the manufac-
turer’s instructions (Dharmacon, Scoresby, New South Wales,
Australia).
Immunofluorescence
Cells were grown on poly-L-lysine-coated glass coverslips and treated
with 2mM ICRF-193 (Biomol) and/or transfected with 25 nM nontarget-
ing siRNA, TopoIIa, and/or TopoIIb siRNAs. Cells were fixed
and immunostained as described previously (Warrener et al., 2010)
with human anti-centromere antibodies serum (centromeres), Aurora
B (BD Biosciences, North Ryde, New South Wales, Australia), a-
Tubulin (Abcam, Waterloo, New South Wales, Australia) antibodies,
4’,6-diamidino-2-phenylindole DNA stain, and appropriate
secondary antibodies.
Chromosome spreads
Cells were treated with 2mM ICRF-193 (Biomol) for 24 hours, and then
with 500mg ml 1 nocodazole for 2 hours before harvesting. Mitotic
cells were harvested by knock off and resuspended in hypertonic
buffer containing 10 mM Tris, pH 7.4, 10 mM NaCl, and 5 mM MgCl2
at 2 105 cells per ml for 10 minutes. Cells were cytospun at
5,000 r.p.m. for 2 minutes onto glass slides. Cells were then fixed
with 4% paraformaldehyde for 10 minutes and stained with 4’,6-
diamidino-2-phenylindole DNA stain.
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